A study of QL1706 for HR-positive, HER2-negative breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug combination (iparomlimab and tuvonralimab, also called QL1706) for people with advanced breast cancer that is hormone receptor-positive and HER2-negative. It may be an option if standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- Your breast cancer has spread or come back and cannot be removed with surgery.
- Your tumor is hormone receptor-positive (ER and/or PR positive) and HER2-negative.
- You have not had more than 2 types of chemotherapy for advanced disease.
- You have not taken more than 2 CDK4/6 inhibitors for advanced disease.
- You have at least one tumor that can be measured on scans, or you have only bone disease that can be seen on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug QL1706, given before surgery, can help treat hormone receptor positive and HER2-negative breast cancer. It is for people who have not yet had cancer spread to other parts of the body.
This trial tests a combination of an immunotherapy drug (QL1706) plus chemotherapy given before surgery to shrink early high-risk triple-negative breast cancer. The goal is to see if this treatment can improve the chance of a complete response (no cancer left at surgery).
This trial tests a new drug (QL1706) combined with hormone therapy for breast cancer that did not shrink enough with initial chemotherapy. The goal is to see if this combination can improve treatment response before surgery.
This trial tests a new treatment called QL1706 for people with cervical cancer that has come back or spread and has not responded to platinum-based chemotherapy. It aims to see if QL1706 can help shrink tumors and improve outcomes.
This trial tests a combination of two drugs (QL1706 and olaparib) for people with advanced breast cancer that is HER2-negative and has a specific DNA repair problem called HRD. It's for those who have already tried 2 to 4 previous treatments.
This trial tests a new immunotherapy drug (QL1706) combined with a short course of common chemotherapy (anthracyclines or taxanes) for people with early-stage triple-negative breast cancer. The goal is to see if this combination is safe and helps shrink the tumor before surgery.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.